Stockscreener 앱 받기
4.04
18.48%
0.63
시간 외 거래:
4.20
0.16
+3.96%
전일 마감가:
$3.41
열려 있는:
$3.58
하루 거래량:
42.97M
Relative Volume:
7.97
시가총액:
$24.47M
수익:
$1.38M
순이익/손실:
$-179.05M
주가수익비율:
-0.658
EPS:
-6.14
순현금흐름:
$-155.03M
1주 성능:
+194.89%
1개월 성능:
+101.00%
6개월 성능:
+2,348%
1년 성능:
+392.56%
1일 변동 폭
$3.5708
$4.68
1주일 범위
$1.575
$4.68
52주 변동 폭
$0.16
$6.83
바이오엑셀 테라퓨틱스 Stock (BTAI) Company Profile
명칭
Bioxcel Therapeutics Inc
전화
203-643-8060
주소
555 LONG WHARF DRIVE, NEW HAVEN, CT
BTAI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
4.04 | 20.11M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오엑셀 테라퓨틱스 Stock (BTAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-07-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-01 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-06 | 재확인 | BofA Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-30 | 개시 | Goldman | Buy |
| 2020-09-02 | 개시 | Jefferies | Buy |
| 2020-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-04 | 개시 | Guggenheim | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
모두보기
바이오엑셀 테라퓨틱스 주식(BTAI)의 최신 뉴스
Bioxcel Therapeutics (BTAI.O) Surges 12.6% Without Fundamental Catalyst: A Technical and Order-Flow Deep Dive - AInvest
Bioxcel Therapeutics (BTAI) Surges 28% on Intraday Rally: What’s Fueling the Momentum? - AInvest
BTAI Surges 27% on Unprecedented Momentum: What’s Fueling the Biotech Breakout? - AInvest
Top Penny Stocks to Watch: Ainos, SG Blocks, and BioXcel Therapeutics - AInvest
BioXcel Therapeutics Sees Stock Surge Amid Positive Phase 3 Results in At-Home Trial - timothysykes.com
Best Penny Stocks To ConsiderAugust 5th - MarketBeat
BioXcel Therapeutics Stock (BTAI) Opinions on Phase 3 SERENITY Trial Completion - Quiver Quantitative
BioXcel Therapeutics Anticipates Major Breakthrough with Completion of SERENITY At-Home Trial - StocksToTrade
Bioxcel Therapeutics (BTAI.O) Surges 17.17%—What’s Driving the Intraday Move? - AInvest
Bioxcel Therapeutics shares rise 4.38% premarket after publication in Frontiers in Pharmacology. - AInvest
Bioxcel Therapeutics Soars 11.11% on Positive Drug Study - AInvest
BioXcel Study Highlights Dexmedetomidine’s Potential Benefits - TipRanks
Bioxcel Therapeutics shares rise 11.78% premarket after positive study results for BXCL501 in chronic psychiatric disorders. - AInvest
BioXcel study shows dexmedetomidine reduces stress behaviors By Investing.com - Investing.com Nigeria
BioXcel study shows dexmedetomidine reduces stress behaviors - Investing.com India
BTAI files 424B5 to sell up to $3.5M in stock via ATM program - Stock Titan
BioXcel Therapeutics Announces Publication in Frontiers in - GlobeNewswire
Breakthrough Study: BioXcel's BXCL501 Could Transform Treatment of Chronic Psychiatric Disorders - Stock Titan
Mizuho Securities Maintains Hold Rating for Bioxcel Therapeutics with $2.00 Price Target - AInvest
Bioxcel Therapeutics Soars 27% Intraday: What's Fueling This Biotech Surge? - AInvest
BioXcel’s Clinical Breakthrough Marks Market Anticipation - timothysykes.com
Bioxcel Therapeutics (BTAI.O) Surges 13.39%: What’s Behind the Unusual Intraday Move? - AInvest
3 Penny Stocks to Watch: Tenon Medical, BioXcel Therapeutics, I-Mab - AInvest
Why Did Bioxcel Therapeutics Drop 6.69%? - AInvest
Bioxcel Therapeutics: Buy Rating Driven by SERENITY Trial Milestone and Strategic Expansion. - AInvest
BioXcel Therapeutics, Inc.Common Stock (Nasdaq:BTAI) Stock Quote - FinancialContent
Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright reiterates Buy rating on BioXcel Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy rating on BioXcel Therapeutics stock - Investing.com
Bioxcel Therapeutics (BTAI) Surges 29.9% on Phase 3 Trial Completion — What’s Next for the Biotech Breakout? - AInvest
BioXcel Therapeutics Stock Unveiled: Rollercoaster Insights - StocksToTrade
BioXcel Therapeutics Surges: What’s Behind the Move? - timothysykes.com
Bioxcel Therapeutics: Buy Rating Driven by SERENITY Trial Milestone and Strategic Expansion - TipRanks
What makes BioXcel Therapeutics Inc. stock price move sharplyBuild wealth faster with consistent growth stocks - Jammu Links News
BioXcel Therapeutics Inc. Stock Analysis and ForecastInvest confidently with real-time market updates - Jammu Links News
What are BioXcel Therapeutics Inc. company’s key revenue driversGet professional guidance for market timing - Jammu Links News
Why is BioXcel Therapeutics Inc. stock attracting strong analyst attentionInvest smarter with data-backed insights - Jammu Links News
Does BioXcel Therapeutics Inc. stock perform well during market downturnsOutstanding investment returns - Jammu Links News
Is it the right time to buy BioXcel Therapeutics Inc. stockInvest confidently with real-time market updates - Jammu Links News
What is the dividend policy of BioXcel Therapeutics Inc. stockGet timely alerts on market opportunities - Jammu Links News
How does BioXcel Therapeutics Inc. generate profit in a changing economyLightning-fast capital gains - Jammu Links News
What institutional investors are buying BioXcel Therapeutics Inc. stockMaximize your portfolio’s earning potential - Jammu Links News
What is BioXcel Therapeutics Inc. company’s growth strategyGain the edge with real-time market data - Jammu Links News
BioXcel Therapeutics Completes Phase 3 Trial, Awaits FDA Decision - StocksToTrade
Reversal Confirmed BioXcel Therapeutics Inc. Stock Rallies Above MAWeekly Hot Picks With Buy Confidence Released - metal.it
How does BioXcel Therapeutics Inc. compare to its industry peersValue Investing Entry Points With Proven Results - Jammu Links News
BioXcel’s Strategic Moves Spark Interest - timothysykes.com
Bioxcel Therapeutics shares surge 51.83% intraday after completing key Phase III trial for IGALMI® in home treatment for bipolar disorder or schizophrenia-related agitation. - AInvest
Bioxcel Therapeutics (BTAI.O) Surges 21%: What’s Really Driving the Move? - AInvest
BioXcel Therapeutics: A Rollercoaster Ride? - StocksToTrade
BioXcel stock surges after completing pivotal Phase 3 trial - Investing.com
바이오엑셀 테라퓨틱스 (BTAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):